ALPINE IMMUNE SCIENCES, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ALPINE IMMUNE SCIENCES, INC. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.43 million as of 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2024-03-20
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.43M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.34M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.67M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.34M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2023-12-31 | $2.43M 10-K · filed 2024-03-20 | |
| 2022-12-31 | $2.34M 10-K · filed 2024-03-20 | |
| 2021-12-31 | $1.67M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $1.34M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $1.59M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $1.38M 10-K · filed 2020-03-30 | |
| 2017-12-31 | $810.00K 10-K · filed 2019-03-18 | |
| 2016-12-31 | $3.00K 10-K · filed 2018-03-28 | $1.22M 10-K · filed 2017-02-13 |